In 1986, Robert John Simes published a provocative article in the Journal of Clinical Oncology. 13 Simes was concerned that a prevalent publication bias in favor of studies that demonstrated positive results might be distorting the oncology literature. He reasoned, ''Clinical trials that fail to show any treatment difference are less likely to be published, and thus, conclusions of therapeutic effectiveness based on a review of only published trials may be seriously misleading.'' 13(p1529) Simes hypothesized that basing a review on studies contained in an international trial registry would be free from such bias. ''Since trials would be registered ab initio with objectives and endpoints clearly stated, their selection in the review would not be influenced by trial results.'' 13(p1529) To test his theory, Simes examined 2 specific questions in cancer treatment: the effectiveness of (1) an initial alkylating agent in comparison with combination chemotherapy for advanced ovarian cancer and (2) the pairing of an alkylating agent and prednisone in comparison with combination chemotherapy for multiple myeloma. For each topic, he synthesized the results of all published randomized clinical trials and compared them with the combined results of randomized trials listed in the International Cancer Research Data Bank (ICRDB).
Simes' suspicion proved prescient: the conclusions resulting from published trials did indeed differ from those derived from the ICRDB. For advance ovarian cancer, the pooled analysis of published trials demonstrated a significant survival advantage for combination chemotherapy, whereas a similar analysis of registered trials demonstrated no difference. For multiple myeloma, both analyses demonstrated an advantage for combination chemotherapy, but the survival ratio was greater in the published trials.
At the time, the ICRDB only included major trials sponsored by the US National Institutes of Health plus a few from other countries. Simes concluded that his study illustrated the need for a truly definitive international registry and emphasized that point by titling his paper ''Publication Bias: The Case for an International Registry of Clinical Trials.'' 13 Eleven years after the publication of Simes' work, The US Food and Drug Administration (FDA) Modernization Act of 1997 mandated the establishment of a registry for trials involving ''serious and life-threatening diseases or conditions.'' The result, the website ClinicalTrials.gov, was launched in 2000. One of the primary motivations expressed for the registry was to assist desperate patients in locating a therapeutic study that might address their own condition. 16 Creating a more transparent and accurate portrait of the research enterprise to facilitate the practice of evidence-based medicine was depicted as an important, related goal.
The initial usage of the registry was not very relevant to orthopaedic sports medicine, since it reflected an emphasis on more serious conditions. Through April 2005, drugs represented 9266 of 16,396 interventions described in 12,926 registered trials, compared with only 151 categorized as devices. In late 2007, however, the Food and Drug Administration Amendments Act (FDAAA) decreed a substantial expansion of the registry to include most interventional trials of drugs, biologics, or devices regulated by the FDA, except for phase 1 drug trials or small feasibility studies of new devices. An interventional study is defined as one in which the interventions are part of a research protocol or would not have been given in the same manner or intensity if the participants were not part of the study. 17 An important provision of the FDAAA required the reporting of the basic results of a study within 12 months of the completion date for the primary outcome. These basic results include participant flow, baseline and demographic characteristics of the study population, primary and secondary outcome measures, and adverse events. As a result of this expansion, ClinicalTrials.gov now contains 129,429 trials in 179 countries. 1 A number of other trial registries, such as the International Clinical Trials Registry Platform (ICTRP) maintained by the World Health Organization, are also now available for prospective investigators. 8 A study in the current issue of The American Journal of Sports Medicine by Chahal et al 3 examines the publication status of sports medicine-related randomized controlled trials that were registered as closed and completed in Clin-icalTrials.gov prior to June 2009.The authors used several different search strategies to sift through the vast number of studies in that database and identify ones that might be classified under the rubric of orthopaedic sports medicine. Studies that specifically evaluated anesthetic interventions or nonoperative treatment of osteoarthritis were excluded. Sports medicine investigations continue to be rarae aves within the huge flock of trials catalogued at ClinicalTrials.gov: Among the 106,309 trials that were registered when Chahal et al wrote their paper, a mere 34 met the inclusion criteria.
Chahal et al searched through 2 databases to determine whether the registered studies had resulted in publication and, if so, whether important discrepancies existed between the details of the registration and the published reports. Although their methodology provided a minimum
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The American Journal of Sports Medicine, Vol. 40, No. 9 DOI: 10.1177/0363546512459510 Ó 2012 American Orthopaedic Society for Sports Medicine 32-month window of opportunity following study closure and completion, the investigators were only able to identify publications for 20 of the eligible trials (58.8%). There was no apparent relationship between the type of sponsorship and the likelihood of publication, although the relatively small number of studies that were industry or government sponsored may have limited the statistical power of this particular facet of the analysis.
Since Chahal et al did not actually interview the authors of the 14 manuscripts for which they could find no corresponding publication, we can only speculate as to the possible reasons for this deficiency. Some studies may have been published but not uncovered; some may still have been in the process of preparation; some may have been submitted and rejected. In some cases, of course, the authors may have made a conscious decision not to submit their work for publication. It has been shown that negative studies take longer than positive ones to be submitted for publication and are less likely to be submitted at all. 6, 10, 12, 15 A negative outcome may certainly dampen author or sponsor enthusiasm for proceeding with publication. In some instances, failure to publish might be a sign that a study was underpowered or otherwise flawed.
Although ClinicalTrials.gov allows authors to revise their original proposal after its initial registration, 80% of the publications differed from the registered version in one of the major parameters examined, including 7 that reported a new primary outcome. Discrepancies were discovered in secondary outcomes in 10 trials, inclusionexclusion criteria in 7, and sample size in 8. These discrepancies are even more surprising considering that 13 of the 20 published trials were registered retrospectively. Finally, only 9 of the 20 publications reported the trial registration number needed to facilitate comparisons between the 2 versions of the study.
Potential explanations for discrepancies between the original registration and the published report of a trial are numerous. They may simply reflect careless writing, or represent intentional changes made by the authors before, during, or after the conduct of the study. The changes might even have occurred during the editing process, at the behest of journal reviewers. Criticism of such discrepancies may sometimes seem like nitpicking, but elevating the status of a minor outcome measure after study completion may be seen as a form of ''data mining'' that risks identifying a random occurrence as an important finding and clouds the distinction between association and causation. 2, 3 Selective reporting of positive results may misrepresent the complete findings. 4, 9 Conversely, since sample sizes are usually calculated based upon the number needed to determine a significant difference in the preselected primary outcome, either retrospectively promoting a secondary outcome to primary status or failing to achieve the planned sample size can produce falsenegative conclusions if no difference is found.
The reason for the large number of retrospective registrations in the cohort of Chahal et al is unclear. Perhaps they reflect the relative novelty of study registration in the field of orthopaedic sports medicine. An alternative explanation, however, is that authors may sometimes only have registered a trial after they had decided to proceed with publication. If this is true, registered trials may represent the visible tip of a submerged iceberg of studies that are conducted but never reported. While full publication of the completed study is the best way to ensure that all valuable data enter the scientific database, the new FDAAA requirement for posting basic results theoretically promises that some sense of the outcome of even unpublished trials will be publically available. Systematic reviewers also have the option of personally contacting the authors of registered but unpublished studies for additional details.
While we should be careful not to reach definitive conclusions from the small number of registered sports medicine trials available to Chahal et al, their findings are consistent with similar studies that have sampled a cross-section of registered trials 4, 9, 11, 18 or have specifically focused on orthopaedics. 7, 14 In fact, the 58.8% publication rate documented by Chahal et al is somewhat higher than the rates reported from the same institution for orthopaedic trauma (43.2%) 7 and joint arthroplasty (22.8%). 14 Public dissemination of the results of clinical trials is vital to maintaining the integrity of the medical database. Failing to report results of completed studies or reporting them selectively raises several ethical issues. The Declaration of Helsinki states, ''Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.'' 5 It is clearly unlikely that any community will benefit from the results of a study if they are never published.
The Declaration of Helsinki goes on to say, ''Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. Negative and inconclusive as well as positive results should be published or otherwise made publicly available.'' 5 Failure to publicize the results of negative studies may lead to the participation of additional subjects in otherwise unnecessary trials or allow ineffective treatments to flourish. Selectively emphasizing positive study results over negative ones may make an article more newsworthy, but it distorts the scientific record. A well-conducted but underpowered negative study may not be useful in isolation, but if it is publically available, its patients may ultimately contribute to the formulation of a more conclusive meta-analysis.
Requirements for registration of interventional clinical trials vary greatly according to local regulatory standards and the nature of the intervention being investigated. The AJSM strongly recommends that all investigators contemplating a prospective clinical trial enroll it in one of the several available registries, whether or not they are required by law to do so. Authors of registered trials are asked to report the registration identification number for inclusion in the final publication.
